JP2025503096A5 - - Google Patents

Info

Publication number
JP2025503096A5
JP2025503096A5 JP2024543372A JP2024543372A JP2025503096A5 JP 2025503096 A5 JP2025503096 A5 JP 2025503096A5 JP 2024543372 A JP2024543372 A JP 2024543372A JP 2024543372 A JP2024543372 A JP 2024543372A JP 2025503096 A5 JP2025503096 A5 JP 2025503096A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
radioactive nuclide
composite according
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/051355 external-priority patent/WO2023139203A1/en
Publication of JP2025503096A publication Critical patent/JP2025503096A/ja
Publication of JP2025503096A5 publication Critical patent/JP2025503096A5/ja
Pending legal-status Critical Current

Links

JP2024543372A 2022-01-21 2023-01-20 がんの処置および撮像のための複合体 Pending JP2025503096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22152725.2 2022-01-21
EP22152725 2022-01-21
PCT/EP2023/051355 WO2023139203A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Publications (2)

Publication Number Publication Date
JP2025503096A JP2025503096A (ja) 2025-01-30
JP2025503096A5 true JP2025503096A5 (https=) 2026-03-11

Family

ID=79927204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543372A Pending JP2025503096A (ja) 2022-01-21 2023-01-20 がんの処置および撮像のための複合体

Country Status (6)

Country Link
US (1) US20250099631A1 (https=)
EP (1) EP4466032A1 (https=)
JP (1) JP2025503096A (https=)
CN (1) CN118891066A (https=)
AU (1) AU2023208408A1 (https=)
WO (1) WO2023139203A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers

Similar Documents

Publication Publication Date Title
Nishijima et al. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy
Kaplan et al. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation
Lane et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F (ab') 2 antibodies
Rousseau et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
Anderson et al. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223
Cederkrantz et al. Absorbed doses and risk estimates of 211At-MX35 F (ab') 2 in intraperitoneal therapy of ovarian cancer patients
Kao et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile
JP2005532262A5 (https=)
Ferro-Flores et al. Pharmacokinetics and dosimetry of 188Re-pharmaceuticals
Arazi et al. The treatment of solid tumors by alpha emitters released from 224Ra-loaded sources—internal dosimetry analysis
JP2020528059A5 (https=)
Rowlinson et al. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration
JP2025503096A5 (https=)
Banerjee et al. Radiation and radioisotopes for human healthcare applications
Riva et al. Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies
Milner et al. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours
Akgun et al. Therapeutic applications of radiopharmaceuticals: an overview
Riva et al. Radioimmunotherapy of CMS Malignant Gliomas by Direct Intralesional Injection of Specific 131| Radiolabeled Monoclonal Antibodies
Narwadkar et al. Clinical Internal dosimetry and biodistribution of 177Lu-DOTA-trastuzumab in HER2-positive metastatic and locally advanced breast carcinoma
McQuarrie et al. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients
Zhukovsky et al. Dose coefficients for monoclonal antibodies and antibody fragments labeled by zirconium-89
Stabin The importance of patient-specific dose calculations in nuclear medicine
JP2025503096A (ja) がんの処置および撮像のための複合体
Zakaly et al. Internal dosimetry modelling for 89Zr-labelled chimeric monoclonal antibody U36 based on real clinical results
Ryan et al. KADIATION ABSORBED DOSE ESTIMATE FOR RDBIDIOM-82 DETEIMZNED FROM IN VIVO MEASUREMENTS IN HUMAN SUBJECTS